Can I Stay on 1mg Wegovy, or Do I Have to Keep Going Up?

Is 1mg a maintenance dose, or is it a stepping stone?

This is probably the most common misconception people bring to this question. Many assume that if side effects have settled and they're losing weight steadily, they've found their dose. That's understandable. The reality, though, is that 1mg sits in the middle of the Wegovy titration pathway rather than at its intended end point.

The NHS medicines page for semaglutide describes the standard schedule as moving through 0.25mg, 0.5mg, 1mg, 1.7mg and finally 2.4mg, with around four weeks at each level. The 2.4mg weekly injection is the licensed maintenance dose for weight management, the one most of the STEP trial evidence was gathered at. Staying permanently at 1mg means you're working with roughly half the maintenance dose, which typically produces less weight loss over time than the full course would.

None of that means pausing at 1mg is wrong. It means the decision deserves a proper conversation rather than a quiet assumption that things are fine as they are. If you're wondering how earlier doses compare, the question of staying on a lower Wegovy dose is worth reading alongside this page, and there are dedicated pages covering whether staying on 0.5mg is an option and whether remaining on 0.25mg might be appropriate for those earlier in the titration schedule.

So when would a prescriber actually agree to keep you at 1mg?

There are legitimate clinical reasons to hold at a given dose, and prescribers do it regularly. The most common are ongoing gastrointestinal side effects that haven't fully settled (nausea, loose stools, reflux) that are manageable at 1mg but would likely worsen with a jump to 1.7mg. A prescriber may also hold the dose if you've recently had an illness, a surgical procedure, or another change in your health picture that makes further escalation premature.

Some people lose weight steadily at 1mg and their prescriber judges that the benefit-to-tolerability balance argues for staying put rather than pushing higher. That's a valid outcome; clinical practice isn't always about reaching the maximum dose. What it isn't, though, is something you should decide alone by simply not ordering the next strength. The prescriber needs to know you want to pause, review why, and document it, partly for your safety, and partly because clinical review before every repeat is how responsible prescribing works.

The full Wegovy dose overview explains what each step in the schedule is for, which can help frame that conversation.

What if you're not losing weight at 1mg, should you go up or stop?

Slow or stalled weight loss at 1mg is usually a reason to continue up the schedule rather than to stay put. The STEP 1 trial, published in the New England Journal of Medicine, showed that the greatest average reductions (around 15% of body weight over 68 weeks) were achieved at the 2.4mg maintenance dose. Intermediate doses contribute to tolerability and gradual adaptation, but the therapeutic effect builds with the dose.

If you've been on 1mg for longer than the standard four-week window and progress has plateaued, your prescriber is likely to recommend moving to 1.7mg rather than staying. On the other hand, if progress has genuinely stalled even after reaching maintenance and the highest tolerated dose has been sustained for six months, NICE guidance on semaglutide (TA875) notes that continuing should be reviewed. The two situations are quite different, and only a clinical review separates them properly.

For context on holding at 1.7mg instead, there's a separate page covering that specific question.

How does a clinical review at nume handle this?

At nume, every repeat order goes back to a GPhC-registered prescriber, a real clinician reads your case, not software working through a checklist. If you want to discuss pausing at 1mg, that's exactly the kind of thing the repeat review is for. You can flag it, your prescriber considers it against your progress and history, and a documented decision is made either way.

What that means in practice: you're not left to self-manage a dose-hold in silence, and you're not pressured to escalate before you're ready. The Wegovy treatment overview sets out the broader picture of how the medicine works and what to expect over the course of treatment. If you're still working out whether Wegovy is the right route for you, our weight-loss treatment page covers the options available through a private prescription.

Side effects during titration are also worth understanding in full before any dose decision. The NHS's semaglutide side-effects page gives a plain-language rundown of what to expect and when to seek help. And if a question about your treatment isn't covered here, the FAQs page is a practical first stop before reaching out directly.

When you're ready to talk it through with a prescriber, start your free consultation and our clinical team will take it from there.